Source:http://linkedlifedata.com/resource/pubmed/id/19882983
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2009-11-3
|
pubmed:abstractText |
Tebipenem pivoxil (TBPM-PI), the first oral carbapenem antibiotic both in Japan and abroad, was examined on its convulsive liability. We used ICR male mice and Sprague-Dawley male rats to examine the pro-convulsive effect and anticonvulsive effect of TBPM-PI and its active metabolite, TBPM. (1) When mice were treated with TBPM-PI (30-1000 mg/kg, p.o.) or TBPM (10-300 mg/kg, i.v.), no convulsion was noted at any dose level. When rats were treated with TBPM (300 mg/kg, i.v.), no convulsant effects were noted in electroencephalography or behavioral observation. In intraventricular injection of TBPM in mice, clonic convulsion was observed in 7/10 animals at 100 microg but no effect at 30 microg. On the other hand, the administration of 10/10 microg imipenem/cilastatin (IPM/CS) resulted in clonic convulsion in all animals and tonic convulsion in 3/10 animals, and 4/10 animals died. The administration of 100 microg meropenem did not cause any effects. (2) When mice were co-administered with pentylenetetrazole (45 mg/kg: maximum dose level at which no convulsion is induced) and TBPM-PI (30-300 mg/kg, p.o.) or TBPM (300 mg/kg, i.v.), convulsion enhancing effect was not noted. On the other hand, the co-administration of pentylenetetrazole with IPM/CS (300/300 mg/kg, i.v.) enhanced a convulsive effect of pentylenetetrazole. (3) When mice were treated with TBPM-PI (30-300 mg/kg, p.o.) or TBPM (100 mg/kg, i.v.), inhibitory effect was not noted on convulsions induced by electrostimulation, pentylenetetrazole or strychinine. In conclusion, there were no pro-convulsive effects or anticonvulsive effect in the oral administration of TBPM-PI or intravenous administration of TBPM. Pro-convulsive effect was observed in the intraventricular injection of TBPM as in the case of other carbapenem antibiotics, but such action was weaker than that in IPM/CS administration. Accordingly, the risk of occurrence of convulsion related to TBPM-PI administration was low compared to IPM/CS administration, and TBPM-PI was considered to be less potential to induce convulsions in clinical use.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Carbapenems,
http://linkedlifedata.com/resource/pubmed/chemical/Cilastatin,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Imipenem,
http://linkedlifedata.com/resource/pubmed/chemical/Pentylenetetrazole,
http://linkedlifedata.com/resource/pubmed/chemical/cilastatin, imipenem drug...,
http://linkedlifedata.com/resource/pubmed/chemical/tebipenem
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0368-2781
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
62
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
241-52
|
pubmed:meshHeading |
pubmed-meshheading:19882983-Administration, Oral,
pubmed-meshheading:19882983-Animals,
pubmed-meshheading:19882983-Carbapenems,
pubmed-meshheading:19882983-Cilastatin,
pubmed-meshheading:19882983-Dose-Response Relationship, Drug,
pubmed-meshheading:19882983-Drug Combinations,
pubmed-meshheading:19882983-Drug Synergism,
pubmed-meshheading:19882983-Imipenem,
pubmed-meshheading:19882983-Infusions, Intravenous,
pubmed-meshheading:19882983-Injections, Intraventricular,
pubmed-meshheading:19882983-Male,
pubmed-meshheading:19882983-Mice,
pubmed-meshheading:19882983-Pentylenetetrazole,
pubmed-meshheading:19882983-Rats,
pubmed-meshheading:19882983-Seizures
|
pubmed:year |
2009
|
pubmed:articleTitle |
[Convulsive liability of an oral carbapenem antibiotic, tebipenem pivoxil].
|
pubmed:affiliation |
Applied Pharmacology Research Labs., Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
|
pubmed:publicationType |
Journal Article,
English Abstract
|